
Gland Pharma Ltd is Rated Buy by MarketsMOJO
2026-11-21 10:10:33Gland Pharma Ltd is rated Buy by MarketsMOJO, with this rating last updated on 09 Nov 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 21 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 3428
2026-11-16 10:09:01Surging to an intraday peak of Rs 3428 on 16 Nov 2026, Gland Pharma Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement caps an impressive rally that has seen the stock more than double from its 52-week low of Rs 1575, reflecting robust momentum underpinned by a confluence of technical indicators and sustained price strength.
Read MoreGland Pharma Gains 5.22%: 4 Key Factors Driving the Week’s Momentum
2026-11-14 12:00:37Key Events This Week Nov 09: New 52-week high at Rs.3,356 Nov 09: Intraday surge of 7.02% Nov 09: Mojo Grade upgraded to Buy Nov 11: Technical momentum strengthens with bullish signals Nov 13: Week closes at Rs.3,334.70 (+5.22%) Week OpenRs.3,169.40 Week Close<div class="sta...
Read More
Gland Pharma Ltd Upgraded to Buy on Strong Technical and Financial Performance
2026-11-10 08:52:07Gland Pharma Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, financial performance, valuation metrics, and overall quality assessment. The upgrade, effective from 09 Nov 2026, is underpinned by a comprehensive analysis of the company’s recent quarterly results, market-beating returns, and bullish technical trends, signalling renewed investor confidence in this small-cap pharmaceutical player.
Read More
Gland Pharma Ltd Surges 7.02% to Day's High of Rs 3356 — Outperforms Sector by 5.29 Percentage Points
2026-11-09 10:21:58The Sensex declined by 0.22% on 09 Nov 2026, while Gland Pharma Ltd surged 7.02%, touching an intraday high of Rs 3356. This 5.29-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 3356
2026-11-09 09:51:11Surging past its previous peak, Gland Pharma Ltd touched a new 52-week high of Rs 3356 on 09 Nov 2026, marking a remarkable 78.34% gain over the past year. This rally stands in stark contrast to the Sensex’s decline of 2.80% during the same period, underscoring the stock’s strong momentum amid a mixed market backdrop.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 3183.85
2026-11-05 10:17:52With a 66.08% gain over the past year, Gland Pharma Ltd has surged to a new 52-week high of Rs 3183.85 on 5 Nov 2026, significantly outperforming the Sensex which declined 5.57% over the same period. This milestone reflects a powerful technical momentum that has propelled the stock well above all key moving averages, signalling robust price strength in the pharmaceuticals sector.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 3171
2026-11-04 13:11:40With a remarkable 65.55% gain over the past year, Gland Pharma Ltd has surged to a fresh 52-week high of Rs 3,171, closing just 0.03% shy of this milestone on 4 Nov 2026. This rally stands in stark contrast to the Sensex’s 7.71% decline over the same period, underscoring the stock’s strong momentum amid a mixed market backdrop.
Read MoreGland Pharma Gains 9.63%: 3 Key Factors Driving the Week’s Momentum
2026-10-31 13:00:07Key Events This Week 26 Oct: Stock opens at ₹2,843.90, modest gain of 0.66% 27 Oct: Technical momentum shifts signal bullish outlook, stock surges 4.14% to ₹2,961.55 28 Oct: Valuation shifts to very expensive, Mojo Grade upgraded to Buy 29 Oct: Continued gains with 0.90% rise amid mixed technical signals 30 Oct: Week closes at ₹3,097.50, total weekly gain of 9.63% <div class="stat-label...
Read MoreAnnouncement under Regulation 30 (LODR)-Change in Management
20-Nov-2026 | Source : BSEAppointment of Mr. Ajay Sahni as the President of Phixen SAS(wholly owned step down subsidiary of Gland Pharma Limited) with effect from November 30 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17-Nov-2026 | Source : BSESchedule of Investor Meet Intimation
Grant Of Options To Purchase Securities
16-Nov-2026 | Source : BSEGrant of Options to Purchase Securities
Corporate Actions
No Upcoming Board Meetings
Gland Pharma Ltd has declared 2000% dividend, ex-date: 11 Aug 26
No Splits history available
No Bonus history available
No Rights history available